Sham Mailankody

Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval

Vinay Prasad, Sham Mailankody · JAMA Internal Medicine · 2017 · 485 citations

GPRC5D-Targeted CAR T Cells for Myeloma

Sham Mailankody, Sean M. Devlin, Jonathan Landa et al. · New England Journal of Medicine · 2022 · 367 citations · Full text

Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma

Neha Korde, Mark Roschewski, Adriana Zingone et al. · JAMA Oncology · 2015 · 308 citations · Full text

Unintended Consequences of Expensive Cancer Therapeutics—The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity

Tito Fojo, Sham Mailankody, Andrew W. Lo · JAMA Otolaryngology–Head & Neck Surgery · 2014 · 296 citations

Preclinical Therapeutics, Cancer Management, Expensive Therapies +18

Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies

Tania Jain, Andrea Knežević, Martina Pennisi et al. · Blood Advances · 2020 · 252 citations · Full text